These results demonstrate that like NRAS, HRAS, and KRAS4B, oncogenic KRAS4A also possesses leukemogenic activity, though it induces mostly T-ALL like disease rather than myeloid leukemia when palmitoylation is blocked. This evidence concerns the gene KRAS and myeloid leukemia.